“Había vivido una revolución que me había quitado a una parte de mi familia.
Había sobrevivido a una guerra y por poco me mata una banal historia de amor”
Neurogenic Claudication Territories in Lumbar Spinal Stenosis.
📚 Young JJ et al. Digital pain diagrams to identify common lumbar spinal stenosis pain distribution patterns: a cross-sectional latent class analysis. European Spine Journal. 2025.
https://t.co/8YI0D1E2ch
Preliminary investigation. More atypical & heterogeneous than you might think
Authors used digital pain diagrams in 2,379 patients with LSS. 6 clinically recognisable pain distribution classes rather than one classic “textbook” presentation.
📊 Pain distribution classes:
⭕️ Class 1 (11.4%) → Bilateral posterior leg pain
⭕️ Class 2 (8.7%) → Bilateral posterior + anterior leg pain
⭕️ Class 3 (26.1%) → Unilateral posterior leg pain
⭕️ Class 4 (21.0%) → Unilateral posterior leg pain + low back pain
⭕️ Class 5 (22.9%) → Unilateral anterior + posterior leg pain
⭕️ Class 6 (9.9%) → Multisite pain
Clinical take aways👇
⚠️ The “classic” bilateral posterior leg pattern was less common.
⚠️ Unilateral presentations were more common than bilateral ones.
⚠️ Anterior thigh/leg symptoms were common, challenging the idea that LSS is predominantly a posterior calf/buttock condition.
⚠️ Low back pain severity was relatively similar across groups, questioning how diagnostically useful back pain itself may be.
⚠️ Multisite pain presentations existed
So not so neat, entirely fits my biases and observations.
⚠️ Drawbacks: cross-sectional study only, preliminary data, secondary care sample, based on clinical coding rather than imaging-confirmed standards, no symptom-quality mapping or imaging correlation, several common co-morbidities/masqueraders excluded.
This week is peripheral neuropathy awareness week so here are a few useful articles about PN
Ten steps in diagnosing PN
https://t.co/sYjpAhUqjI
The 10 P's
https://t.co/tV6tdqueLX
PN JAMA Review
https://t.co/dsQKfG5oRl
Tests for treatable small-fiber PN
https://t.co/xcNlgFNaXf
🌷La Clínica de Trastornos del Movimiento del @INNNMVS invita a las personas en edad de 50 a 85 años, con diagnóstico de Parkinson de 3 años o menos y con tratamiento de Levodopa (max. 450 mg/día), a participan en el estudio PARAISO-BN44715.
🔍Consulta aqui toda la información.
Gracias a la Dra. Inés González Suárez, el Prof. Jefferson Becker y la Dra. Carmen Tur por la sesión de ayer. También agradecer a todos los que os conectasteis i partners por hacerlo posible.
El debate dejó claro que la decisión de cribar activamente en personas de alto riesgo depende del perfil del paciente, los biomarcadores disponibles y el contexto clínico - sin una respuesta única.
🔜 Próxima sesión - Hot Topics en EM: Cemcat Series, ¿Los criterios de diagnóstico del 2024 aumentan los errores de diagnóstico?
✅ Prof. Àngel Pérez Sempere - Profesor Titular, H. Dr. Balmis, Alicante
❌ Dra. Lucienne Costa-Frossard - CSUR EM, H. Ramón y Cajal, Madrid
🗣️ Modera: Dra. Georgina Arrambide - Cemcat, HUVH, Barcelona
🗓 3 de junio | 16:00 h - 17:00 h(CEST)
➡️ Inscríbete: https://t.co/1BFpqKaoHg
#HotTopics2026 #HotTopicsEM #EsclerosisMúltiple
El grupo de trabajo de trastornos de la conducta y del movimiento durante el sueño de la Sociedad Española de Sueño (SES) ha elaborado una Guía de Práctica Clínica de Diagnóstico de Parasomnias REM en adultos.
Podéis descargarla aquí: https://t.co/nlfOvHsAT8
Key Point 6 from the article Adult-Onset Leukodystrophies Mimicking Multiple Sclerosis by Gabrielle Macaron and Roberta La Piana from the April #MultipleSclerosis and Related Disorders issue, which is available to subscribers at https://t.co/PTU4YDAamM. #NeuroTwitter#MedEd
Progressive MS: once called untreatable. The evidence landscape has shifted - but questions remain 🧬 https://t.co/BwCcyHn2ro
📘 Next Monday, May 4th at (CEST) - new Cemcat International Rounds session: "Treatment of Progressive Disease"
👨🏼⚕️ Dr. @DanOntaneda (Associate Professor of Neurology, Cleveland Clinic Lerner College of Medicine, Cleveland, USA) - leading investigator in progressive MS clinical trials - presents the current evidence and open challenges in treatment of progressive disease.
🗣️ Chaired by Prof. @XMontalban - Neurologist - Professor of Neurology - Multiple Sclerosis Centre of Catalonia (Cemcat), UVic-UCC, Barcelona
➡️ Save your spot and register free: https://t.co/BwCcyHn2ro
#CIR26 #CemcatInternationalRounds #ProgressiveMS #MSResearch
🧩 #MOGAD can mimic #MultipleSclerosis
The TRUE-MOGAD score helps neurologists in these tricky cases, as this patient (@BioMedCentral):
➡️38y, titers 1:100, Focal+MRI features
➡️OCB present, no lesion resolution on follow-up
👉 Score= 1 → acute steroids
❌ <2 → MOGAD unlikely!
High yield and compact lecture for neuroanatomic localization. Highly recommend for junior residents and interns interested in neurology
https://t.co/Es1csYUgan
#MondayTip
Hypoperfusion Intensity Ratio
#HIR may be the most practical collateral biomarker in AIS
⬆️High HIR (>0.4) → rapid core growth, ↑ hemorrhage risk, worse mRS.
⬇️Low HIR → robust collaterals & better EVT outcomes.
https://t.co/wRfh2VnWQ8
🔜 23/03 - New session at Cemcat International Rounds - MS Differential Diagnosis - https://t.co/BmbIx29yoJ
White matter lesions on MRI — but is it really MS? MOGAD, AQP4+ NMOSD, neurosarcoidosis, and CNS vasculitis can all mimic multiple sclerosis. Misdiagnosis may lead to years of inappropriate treatment.
Accurate differential diagnosis requires integrating MRI lesion morphology and distribution, the central vein sign, CSF oligoclonal bands, and serum biomarkers such as AQP4-IgG and MOG-IgG.
With Prof. Eoin P. Flanagan (Mayo Clinic), chaired by Dr. Georgina Arrambide (Cemcat, HUVH)
🗓 March 23, 2026 | 16:00 - 17:00 (CET)
🔗 https://t.co/BwCcyHnAgW
#CemcatInternationalRounds #MSDiagnosis #DifferentialDiagnosis #Neuroimmunology
Spotify oficialmente prohibirá los narcocorridos, corridos bélicos y todo aquel corrido que glorifique el narcotrafico.
Que en paz descanse México 🕊️🇲🇽
Drug-induced myoclonus (DIM)
DIM is more common than clinicians realize
Our systematic review screened 12,097 PubMed articles and identified 1,115 cases of DIM
https://t.co/9tnvrUtL7D
https://t.co/hbOCaB7wmk
#mdpimedicina
via @MdpiMedicina
1/
Tornant als orígens @cemcat_em ! Compartint. Energia, entusiasme i aquella sensació que tot estava per fer.Els sèniors, fidels a la poma reglamentària, al despatx, amb l’agenda plena. Joventut entusiasta i experiència són el que fa gran qualsevol equip!!@ikerelosua